Missing samples [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2019-10-17 10:22  – Posting: # 20700
Views: 4,597

Hi ElMaestro,

» This, I think, relates originally to FDA's data driven policies. A subject can walkout on her/his own initiative without even stating a reason, that's how GCP works. There is no clause saying she/he can't come back.
» I know, this is messy, but that's the way it is in some clinics.

I see. Since the data are useless for the FDA’s reference-scaling maybe this was a trick-shot of the CRO to milk the sponsor.

» The alternative may be worse, depending on how you look at it: If a subject misses an ambulatory pk-sample […] should she/he then be considered completely out?

I like your examples! That’s an area of improvement which requires a good amount of intellectual horsepower. Not easy but the idea is to come up with rules specifying how many missings (and where) in the profile will likely lead to unreliable estimates of a given PK metric.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
20,811 posts in 4,355 threads, 1,448 registered users;
online 16 (1 registered, 15 guests [including 9 identified bots]).
Forum time: 10:23 CEST (Europe/Vienna)

One of the symptoms of an approaching nervous breakdown
is the belief that one’s work is terribly important.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz